Dermata Therapeutics Inc (DRMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dermata Therapeutics Inc (DRMA) has a cash flow conversion efficiency ratio of -0.694x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.42 Million) by net assets ($3.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Dermata Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Dermata Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Dermata Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Dermata Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dermata Therapeutics Inc ranked by their cash flow conversion efficiency. See Dermata Therapeutics Inc (DRMA) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GB Group plc
LSE:GBG
|
0.047x |
|
Magic Empire Global Limited
NASDAQ:MEGL
|
-0.038x |
|
BuilderSmart Public Company Limited
BK:BSM
|
0.083x |
|
Austin Metals Ltd
AU:AYT
|
-0.023x |
|
Maxcom SA
WAR:MXC
|
-0.079x |
|
JLT Mobile Computers AB (publ)
ST:JLT
|
-0.121x |
|
Priti International Limited
NSE:PRITI
|
-0.081x |
|
CARLSON INV. ZY 13
F:2HB
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Dermata Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Dermata Therapeutics Inc from 2019 to 2025. View DRMA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.22 Million | $-7.76 Billion | -1246.519x | -17332.07% |
| 2024-12-31 | $1.56 Million | $-11.16 Million | -7.151x | -609.06% |
| 2023-12-31 | $6.36 Million | $-6.41 Million | -1.008x | +31.26% |
| 2022-12-31 | $6.02 Million | $-8.83 Million | -1.467x | -160.43% |
| 2021-12-31 | $10.11 Million | $-5.69 Million | -0.563x | -144.44% |
| 2020-12-31 | $-3.18 Million | $-4.03 Million | 1.268x | -93.21% |
| 2019-12-31 | $-210.16K | $-3.92 Million | 18.663x | -- |
About Dermata Therapeutics Inc
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in… Read more